Lupin | Page 3 | Business Upturn

Latest Articles

Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets

Corporates · Jun 7, 2025

blank

Top stocks to watch today, May 27: Lupin, Aurobindo Pharma, NHPC, KEC International, Shilpa Medicare and more

Stock Market · May 27, 2025

blank

Lupin and SteinCares sign license and supply agreement for Ranibizumab in Latin America

Corporates · May 26, 2025

blank

Lupin secures FDA approval for Rivaroxaban 10 mg, 15 mg and 20 mg tablets

Corporates · May 15, 2025

blank

Lupin launches Tolvaptan tablets in the US for ADPKD treatment

Corporates · May 13, 2025

blank

Lupin launches Eslicarbazepine Acetate Tablets in the US

Corporates · May 7, 2025

blank

Lupin receives U.S. FDA approval for Tolvaptan tablets with 180-day exclusivity

Corporates · Apr 24, 2025

By Aditya Bhagchandani

blank

Lupin receives EIR from US FDA for its injectable manufacturing facility in Nagpur

Corporates · Apr 17, 2025

blank

Stocks to watch today: Wipro, Zydus, Lupin, KEI, L&T, Bharti Airtel, IndiGo shares in focus on brokerage actions

Stock Market · Apr 17, 2025

blank

Lupin: Business Model, Q3 FY25 Earnings, Promoter Details, and Shareholding Pattern

Corporates · Apr 6, 2025

By Aditya Bhagchandani

blank

Lupin shares jump 6% as U.S. spares pharma exports from 26% tariff

Stock Market · Apr 3, 2025

blank

Lupin receives U.S. FDA approval for 10 mg Amifampridine Tablets

Corporates · Mar 17, 2025

blank

Lupin launches FDA-approved Rivaroxaban Tablets USP, 2.5 mg in the US

Corporates · Mar 7, 2025

blank

Lupin’s Somerset plant receives FDA approval following successful inspection

Corporates · Feb 21, 2025

blank

Lupin shares surge 5% as HSBC maintains ‘Buy’ rating with Rs 2,565 target

Stock Market · Feb 13, 2025

Showing 45 of 87 articles